Illustration: Sarah Grillo/Axios

There's still no settlement in the national opioids case, but plenty of other large health care cases have been laid to rest recently.

The bottom line: Allegations of wrongdoing are rampant in health care. For defendants, it's often easier — and in their interest — to settle and eat the result as a cost of doing business.

Driving the news: None of these companies admitted wrongdoing.

  • Allergan is shelling out $750 million to settle allegations that it used tactics to impede generic competitors to one of its Alzheimer's drugs.
  • 15 drug companies are paying a combined $248 million to resolve allegations they gamed the pricing system to inflate their payments from state Medicaid programs.
  • Sanford Health paid a $20 million settlement to kill a case that accused one of its neurosurgeons of performing unnecessary spine surgeries and profiting from the devices that were used.
  • Two disease-focused nonprofits paid a combined $6 million to clear allegations that pharmaceutical companies were using them as conduits to pay for patients' medications.

Go deeper: Two new articles in JAMA Internal Medicine here and here) highlight the problems with health care settlements — especially when important documents that could affect public health are unearthed but are kept secret.

Go deeper

U.S. economy adds 1.8 million jobs in July

Data: Bureau of Labor Statistics; Chart: Axios Visuals

The U.S. added 1.8 million jobs last month, while the unemployment rate fell to 10.2% from 11.1% in June, the Labor Department said on Friday.

Why it matters: The labor market continued to recover but the pace of job growth slowed significantly from June’s 4.8 million job gain, suggesting a stalled recovery as coronavirus cases surged and states pulled back on reopening plans.

41 mins ago - Sports

The pandemic's impact on how sports are played

Damian Lillard shoots a free throw during one of the NBA's restart games. Photo: Mike Ehrmann/Getty Images

Sports are back, and on the surface, the actual gameplay looks fairly similar to when we last saw them.

But beneath that facade of normalcy lie some interesting trends spurred on by fan-less environments, long layoffs and condensed schedules.

A soaring Nasdaq is just one slice of the buy-anything market

Illustration: Aïda Amer/Axios

The Nasdaq closed above 11,000 for the first time on Thursday, ending the session higher for the seventh time in a row and eighth session in nine. It has gained nearly 10% since July 1.

Why it matters: It's not just tech stocks that have rallied recently. Just about every asset class has jumped in the third quarter, including many that typically have negative or inverse correlations to each other.